Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lee's Pharmaceutical Holdings Limited (HK:0950)
HKEX:0950
Lee's Pharmaceutical Holdings Limited (0950) Stock Price & Analysis
0 Followers
0950 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.99 - HK$1.73
Previous CloseHK$1.21
Volume182.00K
Average Volume (3M)120.78K
Market Cap
HK$712.49M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)42.6
Beta0.44
Next Earnings
Aug 29, 2024EPS EstimateN/A
Last Dividend Ex-Date
May 28, 2024Dividend Yield1.49%
Share Statistics
EPS (TTM)0.03
Shares Outstanding588,835,343
10 Day Avg. Volume673,620
30 Day Avg. Volume120,781
Standard Deviation0.18
R-Squared0.25
Alpha-0.00452
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Lee's Pharmaceutical Holdings Limited News
PremiumCompany Announcements
Lee’s Pharma Grants Millions in Share Options
PremiumCompany Announcements
Lee’s Pharmaceutical AGM Concludes with Full ApprovalsOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
4.72% Mutual Funds
0.02% Other Institutional Investors
95.26% Public Companies and
Individual Investors
0950 FAQ
What was Lee's Pharmaceutical Holdings Limited’s price range in the past 12 months?
Lee's Pharmaceutical Holdings Limited lowest stock price was HK$0.99 and its highest was HK$1.73 in the past 12 months.
What is Lee's Pharmaceutical Holdings Limited’s market cap?
Currently, no data Available
When is Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date?
Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date is Aug 29, 2024 which is in 59 days.
How were Lee's Pharmaceutical Holdings Limited’s earnings last quarter?
Currently, no data Available
Is Lee's Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Lee's Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Lee's Pharmaceutical Holdings Limited pay dividends?
Lee's Pharmaceutical Holdings Limited pays a Annually dividend of <HK$0.01 which represents an annual dividend yield of 1.49%. See more information on Lee's Pharmaceutical Holdings Limited dividends here
What is Lee's Pharmaceutical Holdings Limited’s EPS estimate?
Lee's Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lee's Pharmaceutical Holdings Limited have?
Lee's Pharmaceutical Holdings Limited has 588,835,300 shares outstanding.
What happened to Lee's Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lee's Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:0950
---
Lee's Pharmaceutical Holdings Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.26%
12-Months-Change
Fundamentals
Return on Equity
0.84%
Trailing 12-Months
Asset Growth
3.91%
Trailing 12-Months
Company Description
Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Ltd is a Cayman Island-based research-driven and market-oriented biopharmaceutical company. It is integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales, and marketing in China with global perspectives. It focuses on cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics. Its portfolio has two categories of Proprietary products and Licensed-in products. Its maximum revenue is generated from China. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase and Eyprotor. Its Licensed-in Products include Carnitene, Ferplex, ALOXI and Centraxal Plus, among others.
---
Technical Analysis
Tian Teck Land Limited
―
China Suntien Green Energy Corporation Limited Class H
―
Best Analysts Covering 0950
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a sell rating 10 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---